Molina Healthcare, Inc.
Molina Healthcare, Inc. (MOH) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Molina Healthcare, Inc. (MOH), featuring income statements, balance sheets, and cash flow data.
Molina Healthcare, Inc. (MOH) Income Statement & Financial Overview
Review Molina Healthcare, Inc. MOH income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $11.15B | $10.50B | $10.34B | $9.86B |
| Cost of Revenue | $9.87B | $9.39B | $9.15B | $8.67B |
| Gross Profit | $1.28B | $1.11B | $1.19B | $1.19B |
| Gross Profit Ratio | $0.11 | $0.11 | $0.11 | $0.12 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $774.00M | $665.00M | $676.00M | $691.00M |
| Operating Expenses | $847.00M | $733.00M | $722.00M | $1.08B |
| Total Costs & Expenses | $10.71B | $10.12B | $9.87B | -$9.45B |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $43.00M | $34.00M | $29.00M | $28.00M |
| Depreciation & Amortization | $48.00M | $48.00M | $47.00M | $46.00M |
| EBITDA | $481.00M | $428.00M | $514.00M | $480.00M |
| EBITDA Ratio | $0.04 | $0.04 | $0.05 | $0.05 |
| Operating Income | $433.00M | $380.00M | $467.00M | $434.00M |
| Operating Income Ratio | $0.04 | $0.04 | $0.05 | $0.04 |
| Other Income/Expenses (Net) | -$43.00M | -$34.00M | -$29.00M | -$28.00M |
| Income Before Tax | $390.00M | $346.00M | $438.00M | $406.00M |
| Income Before Tax Ratio | $0.03 | $0.03 | $0.04 | $0.04 |
| Income Tax Expense | $92.00M | $95.00M | $112.00M | $105.00M |
| Net Income | $298.00M | $251.00M | $326.00M | $301.00M |
| Net Income Ratio | $0.03 | $0.02 | $0.03 | $0.03 |
| EPS | $5.47 | $4.37 | $5.66 | $5.20 |
| Diluted EPS | $5.45 | $4.35 | $5.65 | $5.17 |
| Weighted Avg Shares Outstanding | $54.60M | $57.40M | $57.60M | $57.90M |
| Weighted Avg Shares Outstanding (Diluted) | $54.80M | $57.70M | $57.70M | $58.20M |
Over the past four quarters, Molina Healthcare, Inc. demonstrated steady revenue growth, increasing from $9.86B in Q2 2024 to $11.15B in Q1 2025. Operating income reached $433.00M in Q1 2025, maintaining a consistent 4% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $481.00M, reflecting operational efficiency. Net income rose to $298.00M, with EPS at $5.47. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan